Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune, inflammatory disease of the central nervous system (CNS), which causes damage to myelin and axons, resulting in neurological symptoms such as partial loss of sight, paresthesias and ataxia.

Multiple Sclerosis Products Targets

Products for Multiple Sclerosis - Page 24

Cat.No. Product Name Information/Activity
BCC6828 Palmitoylethanolamide Impulsin (AM 3112) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
BCC6341 4-[4-(3-Hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM.
BCC7413 ZK 756326 874911-96-3
BCC7572 BMS CCR2 22 BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM).
BCC6029 BX 471 BX471 (ZK-811752) is an orally active, potent and selective non-peptide CCR1 antagonist with a Ki of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
BCC6047 C 021 dihydrochloride Potent CCR4 antagonist
BCC5909 DAPTA DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
BCC1646 INCB 3284 dimesylate INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC50 of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.
BCC7422 J 113863 J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect.
BCC3675 Maraviroc Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.